Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pyridoxamine - Kowa

Next Previous
Drug Profile

Pyridoxamine - Kowa

Alternative Names: BST-4001; K-163; K163SZ; Pyridorin; Pyridoxamine dihydrochloride; Pyridoxamine hydrochloride

Latest Information Update: 21 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioStratum
  • Developer Kowa; NephroGenex
  • Class Antipsychotics; Picolines; Small molecules
  • Mechanism of Action Advanced glycosylation end product inhibitors; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic nephropathies

Highest Development Phases

  • Phase II Schizophrenia
  • No development reported Acute kidney injury
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 14 Apr 2021 Pyridoxamine is still in phase II trials for Schizophrenia in Japan (JapicCTI-173780) (Kowa pipeline, April 2021)
  • 14 Apr 2021 Discontinued - Phase-III for Diabetic nephropathies in Spain, USA, Puerto Rico, Poland, Mauritius, France, Israel, Hong Kong, Germany, Hungary, Australia, Bulgaria (PO)
  • 28 Jun 2018 No recent reports of development identified for preclinical development in Acute kidney injury in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top